Search Results - "Bladè, Joan"

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma by Medina, Alejandro, Puig, Noemi, Flores-Montero, Juan, Jimenez, Cristina, Sarasquete, M.-Eugenia, Garcia-Alvarez, María, Prieto-Conde, Isabel, Chillon, Carmen, Alcoceba, Miguel, Gutierrez, Norma C., Oriol, Albert, Rosinol, Laura, Bladè, Joan, Gironella, Mercedes, Hernandez, Miguel T., Gonzalez-Calle, Veronica, Cedena, Maria-Teresa, Paiva, Bruno, San-Miguel, Jesus F., Lahuerta, Juan-Jose, Mateos, Maria-Victoria, Martinez-Lopez, Joaquin, Orfao, Alberto, Gonzalez, Marcos, Garcia-Sanz, Ramon

“…Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have…”
Get full text

Monoclonal Gammopathy of Undetermined Significance by BLADE, Joan

“…A 58-year-old man with no significant medical history is found to have an elevated total protein concentration (8.1 g per deciliter) on a routine blood…”
Get full text

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma by Mateos, María-Victoria, Hernández, Miguel-Teodoro, Giraldo, Pilar, de la Rubia, Javier, de Arriba, Felipe, Corral, Lucía López, Rosiñol, Laura, Paiva, Bruno, Palomera, Luis, Bargay, Joan, Oriol, Albert, Prosper, Felipe, López, Javier, Olavarría, Eduardo, Quintana, Nuria, García, José-Luis, Bladé, Joan, Lahuerta, Juan-José, San Miguel, Jesús-F

“…Certain clinical features predict progression from smoldering to overt multiple myeloma. Patients with high-risk features who were treated with lenalidomide…”
Get full text

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma by Kumar, Shaji, Prof, Paiva, Bruno, PhD, Anderson, Kenneth C, Prof, Durie, Brian, Prof, Landgren, Ola, MD, Moreau, Philippe, Prof, Munshi, Nikhil, Prof, Lonial, Sagar, MD, Bladé, Joan, Prof, Mateos, Maria-Victoria, Prof, Dimopoulos, Meletios, Prof MD, Kastritis, Efstathios, MD, Boccadoro, Mario, Prof, Orlowski, Robert, Prof, Goldschmidt, Hartmut, Prof, Spencer, Andrew, Prof, Hou, Jian, Prof, Chng, Wee Joo, Prof, Usmani, Saad Z, MD, Zamagni, Elena, MD, Shimizu, Kazuyuki, Prof, Jagannath, Sundar, Prof, Johnsen, Hans E, Prof, Terpos, Evangelos, MD, Reiman, Anthony, Prof, Kyle, Robert A, Prof, Sonneveld, Pieter, Prof, Richardson, Paul G, Prof, McCarthy, Philip, Prof, Ludwig, Heinz, Prof, Chen, Wenming, Prof, Cavo, Michele, Prof, Harousseau, Jean-Luc, Prof, Lentzsch, Suzanne, Prof, Hillengass, Jens, MD, Palumbo, Antonio, Prof, Orfao, Alberto, Prof, Rajkumar, S Vincent, Prof, Miguel, Jesus San, Prof, Avet-Loiseau, Herve, Prof

“…Summary Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have…”
Get full text

Extramedullary disease in multiple myeloma: a systematic literature review by Bladé, Joan, Beksac, Meral, Caers, Jo, Jurczyszyn, Artur, von Lilienfeld-Toal, Marie, Moreau, Philippe, Rasche, Leo, Rosiñol, Laura, Usmani, Saad Z., Zamagni, Elena, Richardson, Paul

“…Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone…”
Get full text

Clinical practice. Monoclonal gammopathy of undetermined significance by Bladé, Joan

Get full text

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial by Lonial, Sagar, Prof, Weiss, Brendan M, Prof, Usmani, Saad Z, Prof, Singhal, Seema, Prof, Chari, Ajai, Prof, Bahlis, Nizar J, Prof, Belch, Andrew, Prof, Krishnan, Amrita, Prof, Vescio, Robert A, Prof, Mateos, Maria Victoria, Prof, Mazumder, Amitabha, Prof, Orlowski, Robert Z, Prof, Sutherland, Heather J, Prof, Bladé, Joan, Prof, Scott, Emma C, Prof, Oriol, Albert, MD, Berdeja, Jesus, MD, Gharibo, Mecide, Prof, Stevens, Don A, MD, LeBlanc, Richard, Prof, Sebag, Michael, Prof, Callander, Natalie, Prof, Jakubowiak, Andrzej, Prof, White, Darrell, Prof, de la Rubia, Javier, Prof, Richardson, Paul G, Prof, Lisby, Steen, MD, Feng, Huaibao, PhD, Uhlar, Clarissa M, PhD, Khan, Imran, MD, Ahmadi, Tahamtan, MD, Voorhees, Peter M, Prof

“…Summary Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs…”
Get full text

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma by Rosiñol, Laura, Oriol, Albert, Rios, Rafael, Sureda, Anna, Blanchard, María Jesús, Hernández, Miguel Teodoro, Martínez-Martínez, Rafael, Moraleda, Jose M., Jarque, Isidro, Bargay, Juan, Gironella, Mercedes, de Arriba, Felipe, Palomera, Luis, González-Montes, Yolanda, Martí, Josep M., Krsnik, Isabel, Arguiñano, Jose M., González, Maria Esther, González, Ana Pilar, Casado, Luis Felipe, López-Anglada, Lucia, Paiva, Bruno, Mateos, Maria-Victoria, San Miguel, Jesus F., Lahuerta, Juan-José, Bladé, Joan

“…Achieving and maintaining a high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012…”
Get full text

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma by Palumbo, Antonio, Hajek, Roman, Delforge, Michel, Kropff, Martin, Petrucci, Maria Teresa, Catalano, John, Gisslinger, Heinz, Wiktor-Jędrzejczak, Wiesław, Zodelava, Mamia, Weisel, Katja, Cascavilla, Nicola, Iosava, Genadi, Cavo, Michele, Kloczko, Janusz, Bladé, Joan, Beksac, Meral, Spicka, Ivan, Plesner, Torben, Radke, Joergen, Langer, Christian, Yehuda, Dina Ben, Corso, Alessandro, Herbein, Lindsay, Yu, Zhinuan, Mei, Jay, Jacques, Christian, Dimopoulos, Meletios A

“…Patients treated with an induction regimen of melphalan, prednisone, and lenalidomide followed by lenalidomide maintenance therapy had longer progression-free…”
Get full text

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma by Martinez-Lopez, Joaquin, Lahuerta, Juan J., Pepin, François, González, Marcos, Barrio, Santiago, Ayala, Rosa, Puig, Noemí, Montalban, María A., Paiva, Bruno, Weng, Li, Jiménez, Cristina, Sopena, María, Moorhead, Martin, Cedena, Teresa, Rapado, Immaculada, Mateos, María Victoria, Rosiñol, Laura, Oriol, Albert, Blanchard, María J., Martínez, Rafael, Bladé, Joan, San Miguel, Jesús, Faham, Malek, García-Sanz, Ramón

“…We assessed the prognostic value of minimal residual disease (MRD) detection in multiple myeloma (MM) patients using a sequencing-based platform in bone marrow…”
Get full text

Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach by BLADE, Joan, DE LARREA, Carlos Fernández, ROSINOL, Laura, CIBEIRA, Maria Teresa, JIMENEZ, Raquel, POWLES, Ray

“…We provide an overview on soft-tissue extramedullary plasmacytomas (EMPs) in multiple myeloma (MM). We reviewed the incidence of EMPs in MM, myeloma bone…”
Get full text

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group by Sonneveld, Pieter, Avet-Loiseau, Hervé, Lonial, Sagar, Usmani, Saad, Siegel, David, Anderson, Kenneth C., Chng, Wee-Joo, Moreau, Philippe, Attal, Michel, Kyle, Robert A., Caers, Jo, Hillengass, Jens, San Miguel, Jesús, van de Donk, Niels W.C.J., Einsele, Hermann, Bladé, Joan, Durie, Brian G.M., Goldschmidt, Hartmut, Mateos, María-Victoria, Palumbo, Antonio, Orlowski, Robert

“…The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic…”
Get full text

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study by Rosiñol, Laura, Oriol, Albert, Teruel, Ana Isabel, Hernández, Dolores, López-Jiménez, Javier, de la Rubia, Javier, Granell, Miquel, Besalduch, Joan, Palomera, Luis, González, Yolanda, Etxebeste, Mª Asunción, Díaz-Mediavilla, Joaquín, Hernández, Miguel T., de Arriba, Felipe, Gutiérrez, Norma C., Martín-Ramos, Mª Luisa, Cibeira, Mª Teresa, Mateos, Mª Victoria, Martínez, Joaquín, Alegre, Adrián, Lahuerta, Juan José, San Miguel, Jesús, Bladé, Joan

“…The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,…”
Get full text

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials by SONNEVELD, Pieter, GOLDSCHMIDT, Hartmut, DESAI, Avinash, CAKANA, Andrew, LIU, Kevin, VAN DE VELDE, Helgi, ESSELTINE, Dixie-Lee, MOREAU, Philippe, ROSIÑOL, Laura, BLADE, Joan, JOSE LAHUERTA, Juan, CAVO, Michele, TACCHETTI, Paola, ZAMAGNI, Elena, ATTAL, Michel, LOKHORST, Henk M

“…To characterize efficacy and safety of bortezomib-based versus nonbortezomib-based induction regimens through an integrated analysis of data from phase III…”
Get full text

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients by Paiva, Bruno, Cedena, Maria-Teresa, Puig, Noemi, Arana, Paula, Vidriales, Maria-Belen, Cordon, Lourdes, Flores-Montero, Juan, Gutierrez, Norma C., Martín-Ramos, María-Luisa, Martinez-Lopez, Joaquin, Ocio, Enrique M., Hernandez, Miguel T., Teruel, Ana-Isabel, Rosiñol, Laura, Echeveste, María-Asunción, Martinez, Rafael, Gironella, Mercedes, Oriol, Albert, Cabrera, Carmen, Martin, Jesus, Bargay, Joan, Encinas, Cristina, Gonzalez, Yolanda, Van Dongen, Jacques J.M., Orfao, Alberto, Bladé, Joan, Mateos, Maria-Victoria, Lahuerta, Juan José, San Miguel, Jesús F.

“…The value of minimal residual disease (MRD) in multiple myeloma (MM) has been more frequently investigated in transplant-eligible patients than in elderly…”
Get full text

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome by Beksac, Meral, Seval, Guldane Cengiz, Kanellias, Nicholas, Coriu, Daniel, Rosiñol, Laura, Ozet, Gulsum, Goranova-Marinova, Vesselina, Unal, Ali, Bila, Jelena, Ozsan, Hayri, Ivanaj, Arben, Balić, Lejla Ibricevic, Kastritis, Efstathios, Bladé, Joan, Dimopoulos, Meletios Athanasios

“…Here, we report the outcome of 226 myeloma patients presenting with extramedullary plasmacytoma or paraosseous involvement in a retrospective study conducted…”
Get full text

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma by Chari, Ajai, Martinez-Lopez, Joaquín, Mateos, María-Victoria, Bladé, Joan, Benboubker, Lotfi, Oriol, Albert, Arnulf, Bertrand, Rodriguez-Otero, Paula, Pineiro, Luis, Jakubowiak, Andrzej, de Boer, Carla, Wang, Jianping, Clemens, Pamela L., Ukropec, Jon, Schecter, Jordan, Lonial, Sagar, Moreau, Philippe

“…Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment options and poor survival outcomes. The increasing adoption of…”
Get full text

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma by Sonneveld, Pieter, Dimopoulos, Meletios A., Boccadoro, Mario, Quach, Hang, Ho, P. Joy, Beksac, Meral, Hulin, Cyrille, Antonioli, Elisabetta, Leleu, Xavier, Mangiacavalli, Silvia, Perrot, Aurore, Cavo, Michele, Belotti, Angelo, Broijl, Annemiek, Gay, Francesca, Mina, Roberto, Nijhof, Inger S., van de Donk, Niels W.C.J., Katodritou, Eirini, Schjesvold, Fredrik, Sureda Balari, Anna, Rosiñol, Laura, Delforge, Michel, Roeloffzen, Wilfried, Silzle, Tobias, Vangsted, Annette, Einsele, Hermann, Spencer, Andrew, Hajek, Roman, Jurczyszyn, Artur, Lonergan, Sarah, Ahmadi, Tahamtan, Liu, Yanfang, Wang, Jianping, Vieyra, Diego, van Brummelen, Emilie M.J., Vanquickelberghe, Veronique, Sitthi-Amorn, Anna, de Boer, Carla J., Carson, Robin, Rodriguez-Otero, Paula, Bladé, Joan, Moreau, Philippe

“…The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant…”
Get full text

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma by Paiva, Bruno, Puig, Noemi, Cedena, Maria-Teresa, Rosiñol, Laura, Cordón, Lourdes, Vidriales, María-Belén, Burgos, Leire, Flores-Montero, Juan, Sanoja-Flores, Luzalba, Lopez-Anglada, Lucia, Maldonado, Roberto, de la Cruz, Javier, Gutierrez, Norma C, Calasanz, Maria-Jose, Martin-Ramos, Maria-Luisa, Garcia-Sanz, Ramón, Martinez-Lopez, Joaquin, Oriol, Albert, Blanchard, María-Jesús, Rios, Rafael, Martin, Jesus, Martinez-Martinez, Rafael, Sureda, Anna, Hernandez, Miguel-Teodoro, de la Rubia, Javier, Krsnik, Isabel, Moraleda, Jose-Maria, Palomera, Luis, Bargay, Joan, Van Dongen, Jacques J M, Orfao, Alberto, Mateos, Maria-Victoria, Blade, Joan, San-Miguel, Jesús F, Lahuerta, Juan-José

“…Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain,…”
Get full text

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues by Delforge, Michel, Prof, Bladé, Joan, Prof, Dimopoulos, Meletios A, Prof, Facon, Thierry, Prof, Kropff, Martin, MD, Ludwig, Heinz, Prof, Palumbo, Antonio, Prof, Van Damme, Philip, MD, San-Miguel, Jesús F, Prof, Sonneveld, Pieter, Prof

“…Summary Introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide has substantially improved outcomes for…”
Get full text